Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells

Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells

Background and ObjectivesInhibition of de novo pyrimidine synthesis in proliferating T and B lymphocytes by teriflunomide, a pharmacological inhibitor of dihydroorotate dehydrogenase (DHODH), has been shown to be an effective therapy to treat patients with MS in placebo-controlled phase 3 trials. Ne...

Full description

Bibliographic Details
Main Authors: Gaëlle Tilly, Marion Cadoux, Alexandra Garcia, Jérémy Morille, Sandrine Wiertlewski, Claire Pecqueur, Sophie Brouard, David Laplaud, Nicolas Degauque
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
teriflunomide
CD8 T cells
CD4 T cells
migration
memory T cells
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.730342/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.730342/full

Similar Items